ALLIANCEBERNSTEIN L.P. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 215 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$185,829,567
+24.6%
3,549,075
-3.2%
0.06%
+22.6%
Q1 2024$149,146,060
+16.5%
3,666,324
+5.9%
0.05%
+8.2%
Q4 2023$128,018,130
-0.2%
3,463,694
+3.2%
0.05%
-10.9%
Q3 2023$128,228,843
+332.1%
3,356,776
+308.0%
0.06%
+358.3%
Q2 2023$29,675,655
-4.7%
822,724
+1.0%
0.01%
-7.7%
Q1 2023$31,123,666
-33.1%
814,969
-0.4%
0.01%
-38.1%
Q4 2022$46,538,169
+29.0%
817,894
-10.3%
0.02%
+23.5%
Q3 2022$36,064,000
-16.7%
912,099
-7.3%
0.02%
-15.0%
Q2 2022$43,306,000
+12.4%
984,234
+1.9%
0.02%
+33.3%
Q1 2022$38,519,000
+3.0%
965,871
+3.8%
0.02%
+15.4%
Q4 2021$37,413,000
+16.7%
930,451
+18.1%
0.01%0.0%
Q3 2021$32,058,000
+28.5%
788,058
+43.4%
0.01%
+30.0%
Q2 2021$24,957,000
+56.0%
549,602
+43.2%
0.01%
+42.9%
Q1 2021$15,998,000
-14.8%
383,732
-12.7%
0.01%
-22.2%
Q4 2020$18,768,000
+153.2%
439,417
+55.8%
0.01%
+125.0%
Q3 2020$7,413,000
-16.8%
282,076
-15.1%
0.00%
-20.0%
Q2 2020$8,905,000
+55.8%
332,160
+4.5%
0.01%
+25.0%
Q1 2020$5,717,000
-2.4%
317,760
-3.8%
0.00%
+33.3%
Q4 2019$5,856,000
+11.7%
330,260
-2.3%
0.00%0.0%
Q3 2019$5,243,000
-9.7%
338,0600.0%0.00%
-25.0%
Q2 2019$5,808,000
+13.7%
338,060
+6.6%
0.00%
+33.3%
Q1 2019$5,107,000
+10.6%
317,210
+0.5%
0.00%0.0%
Q4 2018$4,617,000
-12.0%
315,610
+9.3%
0.00%0.0%
Q3 2018$5,248,000
+6.1%
288,824
-1.5%
0.00%0.0%
Q2 2018$4,946,000
-7.7%
293,184
+7.2%
0.00%
-25.0%
Q1 2018$5,360,000
-2.6%
273,584
+0.7%
0.00%0.0%
Q4 2017$5,504,000
+79.3%
271,654
+53.7%
0.00%
+100.0%
Q3 2017$3,069,000
+35.5%
176,6940.0%0.00%0.0%
Q2 2017$2,265,000
+3.3%
176,694
+4.4%
0.00%0.0%
Q1 2017$2,193,000
+28.0%
169,194
-2.4%
0.00%
+100.0%
Q4 2016$1,713,000
-18.2%
173,3940.0%0.00%
-50.0%
Q3 2016$2,095,000
+40.0%
173,3940.0%0.00%
+100.0%
Q2 2016$1,496,000
-8.9%
173,3940.0%0.00%0.0%
Q1 2016$1,642,000
-45.5%
173,394
-0.4%
0.00%
-66.7%
Q4 2015$3,015,000
+26.5%
174,004
-2.0%
0.00%
+50.0%
Q3 2015$2,384,000
-46.5%
177,494
-10.0%
0.00%
-50.0%
Q2 2015$4,453,000
+58.1%
197,2140.0%0.00%
+100.0%
Q1 2015$2,816,000
+48.0%
197,2140.0%0.00%0.0%
Q4 2014$1,903,000
+6.0%
197,2140.0%0.00%0.0%
Q3 2014$1,795,000
-7.9%
197,2140.0%0.00%0.0%
Q2 2014$1,948,000
-18.1%
197,214
+5.3%
0.00%0.0%
Q1 2014$2,378,000
-15.3%
187,217
+0.0%
0.00%
-33.3%
Q4 2013$2,806,000
+35.8%
187,2140.0%0.00%
+50.0%
Q3 2013$2,067,000
+38.7%
187,214
-0.3%
0.00%0.0%
Q2 2013$1,490,000187,7050.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,816,162$195,784,0009.33%
BB BIOTECH AG 5,846,564$57,764,0002.74%
QVT Financial LP 4,556,090$45,014,0002.44%
Parametrica Management Ltd 29,578$292,0002.21%
SECTORAL ASSET MANAGEMENT INC 4,389,682$43,370,0001.84%
Belmont Global Advisors, Inc. 257,000$2,539,0001.83%
HARVEY CAPITAL MANAGEMENT INC 394,550$3,898,0001.40%
Lombard Odier Asset Management (USA) Corp 1,350,000$13,338,0000.70%
IRIDIAN ASSET MANAGEMENT LLC/CT 6,199,685$61,253,0000.63%
Callan Capital, LLC 199,230$1,968,0000.53%
View complete list of HALOZYME THERAPEUTICS INC shareholders